bcbs fep glp 1 coverage MCT2D Upcoming Insurance Changes for GLP-1

Kentucky Medicaid does not currently cover GLP-1 therapy for weight loss, and most commercial plans are following the same pattern

Also showed significant reductions in liver fat (up to 82.4%) and improvements in metabolic parameters Phase 3 (TRIUMPH-4) : The Phase 3 TRIUMPH-4 trial confirmed and exceeded Phase 2 results, demonstrating 28.7% mean weight loss at 68 weeks with the 12 mg dose -- the highest reported for any metabolic peptide in a Phase 3 trial Phase 3 program : Additional Phase 3 trials ongoing for obesity (TRIUMPH-1) and type 2 diabetes (TRANSCEND) MASLD/MASH : Specific trials underway evaluating liver-related endpoints Phase 3 TRIUMPH-4 data have confirmed the Phase 2 promise, though the full Phase 3 program across all indications is still ongoing

Peer review Peer review information Nature Metabolism thanks the anonymous reviewers for their contribution to the peer review of this work

This is because of the special characteristics associated with powders, which allow them to be mixed with fluids and foodstuffs easily